Treatment of Dyslipidaemia in Children
Childhood dyslipidaemia is one of the main traditional cardiovascular risk factors that initiate and exacerbate the atherosclerotic process. Healthcare providers may play a key role in the management of children with lipid abnormalities; however, they have to properly evaluate the normal lipid value...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/9/1078 |
| _version_ | 1797520154823753728 |
|---|---|
| author | Riccardo Fiorentino Francesco Chiarelli |
| author_facet | Riccardo Fiorentino Francesco Chiarelli |
| author_sort | Riccardo Fiorentino |
| collection | DOAJ |
| description | Childhood dyslipidaemia is one of the main traditional cardiovascular risk factors that initiate and exacerbate the atherosclerotic process. Healthcare providers may play a key role in the management of children with lipid abnormalities; however, they have to properly evaluate the normal lipid values and know the available treatment options in children and adolescents. Current guidelines recommend healthy behaviours as the first-line treatment for childhood dyslipidaemia. The therapeutic lifestyle changes should focus on dietary modifications, daily physical activity, reduction in body weight and tobacco smoking cessation. Parents play a key role in promoting their children’s healthy habits. In children with more severe forms of lipid abnormalities and in those who do not benefit from healthy behaviours, pharmacological therapy should be considered. Safe and effective medications are already available for children and adolescents. Statins represent the first-line pharmacological option, while ezetimibe and bile acid sequestrants are usually used as second-line drugs. Despite their limited use in children, other lipid-lowering agents (already approved for adults) are currently available or under study for certain categories of paediatric patients (e.g., familial hypercholesterolemia). Further studies are needed to evaluate the long-term efficacy, safety and tolerability of novel lipid-lowering drugs, especially in children. |
| first_indexed | 2024-03-10T07:52:50Z |
| format | Article |
| id | doaj.art-05050c94a4074e9a87c73c2349f3c819 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T07:52:50Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-05050c94a4074e9a87c73c2349f3c8192023-11-22T12:06:40ZengMDPI AGBiomedicines2227-90592021-08-0199107810.3390/biomedicines9091078Treatment of Dyslipidaemia in ChildrenRiccardo Fiorentino0Francesco Chiarelli1Department of Paediatrics, University of Chieti, 66100 Chieti, ItalyDepartment of Paediatrics, University of Chieti, 66100 Chieti, ItalyChildhood dyslipidaemia is one of the main traditional cardiovascular risk factors that initiate and exacerbate the atherosclerotic process. Healthcare providers may play a key role in the management of children with lipid abnormalities; however, they have to properly evaluate the normal lipid values and know the available treatment options in children and adolescents. Current guidelines recommend healthy behaviours as the first-line treatment for childhood dyslipidaemia. The therapeutic lifestyle changes should focus on dietary modifications, daily physical activity, reduction in body weight and tobacco smoking cessation. Parents play a key role in promoting their children’s healthy habits. In children with more severe forms of lipid abnormalities and in those who do not benefit from healthy behaviours, pharmacological therapy should be considered. Safe and effective medications are already available for children and adolescents. Statins represent the first-line pharmacological option, while ezetimibe and bile acid sequestrants are usually used as second-line drugs. Despite their limited use in children, other lipid-lowering agents (already approved for adults) are currently available or under study for certain categories of paediatric patients (e.g., familial hypercholesterolemia). Further studies are needed to evaluate the long-term efficacy, safety and tolerability of novel lipid-lowering drugs, especially in children.https://www.mdpi.com/2227-9059/9/9/1078childrendyslipidaemiamanagementnon-pharmacological approachpharmacotherapy |
| spellingShingle | Riccardo Fiorentino Francesco Chiarelli Treatment of Dyslipidaemia in Children Biomedicines children dyslipidaemia management non-pharmacological approach pharmacotherapy |
| title | Treatment of Dyslipidaemia in Children |
| title_full | Treatment of Dyslipidaemia in Children |
| title_fullStr | Treatment of Dyslipidaemia in Children |
| title_full_unstemmed | Treatment of Dyslipidaemia in Children |
| title_short | Treatment of Dyslipidaemia in Children |
| title_sort | treatment of dyslipidaemia in children |
| topic | children dyslipidaemia management non-pharmacological approach pharmacotherapy |
| url | https://www.mdpi.com/2227-9059/9/9/1078 |
| work_keys_str_mv | AT riccardofiorentino treatmentofdyslipidaemiainchildren AT francescochiarelli treatmentofdyslipidaemiainchildren |